Rivoceranib

Active substance
Rivoceranib
Domain
Oncology and Hematology
Reason of inclusion in Horizonscan Geneesmiddelen
New medicine (specialité)
Main indication
Stomach cancer
Extended indication
Behandeling van vergevorderde of gemetastaseerd maagkanker 3L

1. Product

Manufacturer
LSK BioPharma
Mechanism of action
Tyrosine kinase inhibitor
Route of administration
Oral
Budgetting framework
Intermural (MSZ)

2. Registration

Registration route
Centralised (EMA)
Submission date
2020
Expected Registration
2021
Orphan drug
Yes
Registration phase
Clinical trials
Additional comments
Fase 3 studie inmiddels afgerond.

3. Therapeutic value

Current treatment options
Capecitabine, en in de toekomst trifluridine / tipiracil
Therapeutic value
No judgement
Duration of treatment
Not found
Frequency of administration
1 times a day
References
NCT03042611

4. Expected patient volume per year

Patient volume

< 78

Market share is generally not included unless otherwise stated.

References
IKNL; expertopinie
Additional comments
Ongeveer 70 patiënten wordt behandeld in de 2e lijn voor gemetastaseerd adenocarcinoom van de maag of gastro-oesofageale overgang. Het aantal patiënten met een slokdarmcarcinoom die in de tweede lijn worden behandeld bedraagt ongeveer 60. In totaal zijn dit dus 130 patiënten. De inschatting is dat hiervan maximaal 60% een derde lijns behandeling krijgt (78 patiënten).

5. Expected cost per patient per year

There is currently nothing known about the expected cost.

6. Potential total cost per year

There is currently nothing known about the possible total cost.

7. Off label use

There is currently nothing known about off label use.

8. Indication extension

Indication extension
Yes
Indication extensions
Liver cancer; Non-small cell lung cancer; Ovarian cancer
References
AdisInsight
Additional comments
De verwachting is echter niet dat deze indicatieuitbreidingen binnen 2 jaar zullen plaatsvinden.

9. Other information

There is currently no futher information available.